RHN001 / RH Nanopharma - LARVOL DELTA

Tc-99m SPECT/CT Clinical Dosimetry Using a Next-Generation CZT Gamma Camera (SNMMI 2026) - "CZT SPECT/CT imaging enables quantitative dosimetry of ⁹⁹ᵐTc-labeled RHN001-Dx, supporting consistent assessment of organ-specific absorbed doses. The compound's dosimetric profiles align with those of established ⁹⁹ᵐTc-PSMA agents, reinforcing its suitability as a diagnostic benchmark for the continued development of the ¹⁸⁸Re-labeled therapeutic counterpart."

Clinical • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Tc-99m SPECT/CT Clinical Dosimetry Using a Next-Generation CZT Gamma Camera (SNMMI 2026) - "CZT SPECT/CT imaging enables quantitative dosimetry of ⁹⁹ᵐTc-labeled RHN001-Dx, supporting consistent assessment of organ-specific absorbed doses. The compound's dosimetric profiles align with those of established ⁹⁹ᵐTc-PSMA agents, reinforcing its suitability as a diagnostic benchmark for the continued development of the ¹⁸⁸Re-labeled therapeutic counterpart."

Clinical • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

A Calibration Workflow for Accurate Quantification of Rhenium-188 in RHN001-Tx for Theranostic Applications. (EANM 2025) - "The calibration factor derived from the certified Iodine-123 standard and Re-188 can be applied in future measurements to ensure that the dose calibrator yields accurate and traceable activity readings. All measurement results were within the expected range, confirming the reliability and validity of the calibration workflow."

Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Production optimisation and quality control testing of RHN001-Tx ( 188 Re-PSMA) per GMP standards (EANM 2025) - "Further scale up to even higher doses is currently under investigation. In summary, RHN001-Tx is now available as a fully GMP compliant material for application within the Rhino trial."

Quantitative 99m Tc-SPECT/CT Dosimetry Using a CZT Gamma Camera: Initial Clinical Experience (EANM 2025) - "The observed dosimetric profiles are consistent with those of other 99m Tc-labeled PSMA agents. Thus highlighting the potential reliability of RHN001 as a generator-produced alternative to PSMA radioligand therapy."

Clinical • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx ( 99m Tc-PSMA) in correlation with tumor burden and its implications for theranostic use (EANM 2025) - No abstract available

Oncology

Clinical Trial Protocol for RHINO trial: Prospective Single-center Phase I/II study of RHN001-Dx/Tx in men with PSMA-positive prostate cancer post adjuvant androgen deprivation therapy and/or taxane-based chemotherapy. (EANM 2025) - No abstract available

Clinical • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of formulation buffers on the radiolysis and stability of RHN001-Tx ( 188 Re-PSMA) (EANM 2025) - No abstract available

Development of Kit-Composition for the Preparation of [99mTc]Tc-PSMA-GCK01 / RHN001-DX (EANM 2024) - "We have successfully adapted a reagent composition for the kit based production of [99mTc]Tc-PSMA-GCK01. Temperature and heating conditions were chosen "conservatively", so that the final kit will provide the product in a broad temperature range of 90 ± 10 °C and reaction times of approx. 15 minutes."

Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: RH Nanopharmaceuticals

New P1 trial